Femke H Bouwman

Summary

Affiliation: VU University Medical Center
Country: The Netherlands

Publications

  1. ncbi request reprint CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment
    F H Bouwman
    Department of Neurology, Alzheimer Centre, VU Medical Center, MB Amsterdam, The Netherlands
    Neurobiol Aging 28:1070-4. 2007
  2. ncbi request reprint Longitudinal changes of CSF biomarkers in memory clinic patients
    F H Bouwman
    Alzheimer Center and Department of Neurology, VU Medical Center, Amsterdam, The Netherlands
    Neurology 69:1006-11. 2007
  3. ncbi request reprint CSF biomarker levels in early and late onset Alzheimer's disease
    Femke H Bouwman
    Alzheimer Center and Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands
    Neurobiol Aging 30:1895-901. 2009
  4. doi request reprint CSF biomarkers in Alzheimer's disease and controls: associations with APOE genotype are modified by age
    Maartje I Kester
    Alzheimer Center and Department of Neurology, VU University Medical Center Amsterdam, Amsterdam, The Netherlands
    J Alzheimers Dis 16:601-7. 2009
  5. ncbi request reprint Diagnostic impact of CSF biomarkers in a local hospital memory clinic
    Maartje I Kester
    Alzheimer Center, Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands
    Dement Geriatr Cogn Disord 29:491-7. 2010
  6. doi request reprint Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease
    Cees Mulder
    Department of Clinical Chemistry, VU University Medical Center, Alzheimer Center, Amsterdam, The Netherlands
    Clin Chem 56:248-53. 2010
  7. doi request reprint Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study
    Jasper D Sluimer
    Alzheimer Centre and Department of Diagnostic Radiology, VU University Medical Center, Amsterdam, The Netherlands
    Neurobiol Aging 31:758-64. 2010
  8. ncbi request reprint CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease
    Niki S M Schoonenboom
    Department of Neurology, Alzheimer Center, VU University Medical Center, 1081 HV Amsterdam, The Netherlands
    Neurobiol Aging 29:669-75. 2008
  9. doi request reprint Variability in longitudinal cerebrospinal fluid tau and phosphorylated tau measurements
    Nicolaas A Verwey
    Neurology Department, VU University Medical Center, Alzheimer Center, Amsterdam, The Netherlands
    Clin Chem Lab Med 46:1300-4. 2008
  10. doi request reprint Serial CSF sampling in Alzheimer's disease: specific versus non-specific markers
    Maartje I Kester
    Alzheimer Center and Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands
    Neurobiol Aging 33:1591-8. 2012

Collaborators

Detail Information

Publications15

  1. ncbi request reprint CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment
    F H Bouwman
    Department of Neurology, Alzheimer Centre, VU Medical Center, MB Amsterdam, The Netherlands
    Neurobiol Aging 28:1070-4. 2007
    ..To study CSF biomarkers, beta-amyloid(1-42) (Abeta(1-42)) and tau, and medial temporal lobe atrophy (MTA) on MRI in their ability to predict dementia in patients with mild cognitive impairment (MCI)...
  2. ncbi request reprint Longitudinal changes of CSF biomarkers in memory clinic patients
    F H Bouwman
    Alzheimer Center and Department of Neurology, VU Medical Center, Amsterdam, The Netherlands
    Neurology 69:1006-11. 2007
    ..We evaluated the natural course of CSF biomarkers in patients with AD, subjective complaints, and mild cognitive impairment (MCI)...
  3. ncbi request reprint CSF biomarker levels in early and late onset Alzheimer's disease
    Femke H Bouwman
    Alzheimer Center and Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands
    Neurobiol Aging 30:1895-901. 2009
    ..To compare CSF levels of beta-amyloid 1-42 (Abeta(1-42)), total tau (tau) and tau phosphorylated at threonine 181 (ptau-181) between AD patients and controls according to age...
  4. doi request reprint CSF biomarkers in Alzheimer's disease and controls: associations with APOE genotype are modified by age
    Maartje I Kester
    Alzheimer Center and Department of Neurology, VU University Medical Center Amsterdam, Amsterdam, The Netherlands
    J Alzheimers Dis 16:601-7. 2009
    ..This suggests that cognitively healthy APOE epsilon4 carriers are more prone to develop AD pathology with aging. For AD patients, this provides support for the existence of subtypes within the disease...
  5. ncbi request reprint Diagnostic impact of CSF biomarkers in a local hospital memory clinic
    Maartje I Kester
    Alzheimer Center, Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands
    Dement Geriatr Cogn Disord 29:491-7. 2010
    ..We examined the impact of these biomarkers in the diagnostic process in a non-academic memory clinic...
  6. doi request reprint Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease
    Cees Mulder
    Department of Clinical Chemistry, VU University Medical Center, Alzheimer Center, Amsterdam, The Netherlands
    Clin Chem 56:248-53. 2010
    ..We have used these markers and evaluated their performance...
  7. doi request reprint Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study
    Jasper D Sluimer
    Alzheimer Centre and Department of Diagnostic Radiology, VU University Medical Center, Amsterdam, The Netherlands
    Neurobiol Aging 31:758-64. 2010
    ..To assess associations between cerebrospinal fluid (CSF) biomarker levels and MRI-based whole-brain atrophy rate in mild cognitive impairment (MCI) and Alzheimer's disease (AD)...
  8. ncbi request reprint CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease
    Niki S M Schoonenboom
    Department of Neurology, Alzheimer Center, VU University Medical Center, 1081 HV Amsterdam, The Netherlands
    Neurobiol Aging 29:669-75. 2008
    ..Atrophy of the medial temporal lobe (MTA) on magnetic resonance imaging (MRI) reflects neuronal loss in this area...
  9. doi request reprint Variability in longitudinal cerebrospinal fluid tau and phosphorylated tau measurements
    Nicolaas A Verwey
    Neurology Department, VU University Medical Center, Alzheimer Center, Amsterdam, The Netherlands
    Clin Chem Lab Med 46:1300-4. 2008
    ..The influence of assay variation and duration of storage on changes in cerebrospinal fluid (CSF) levels of tau and phosphorylated (P)-tau with time was evaluated in 112 patients with various neurological disorders...
  10. doi request reprint Serial CSF sampling in Alzheimer's disease: specific versus non-specific markers
    Maartje I Kester
    Alzheimer Center and Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands
    Neurobiol Aging 33:1591-8. 2012
    ..Contrary to AD-specific markers, nonspecific CSF biomarkers, most notably isoprostane, showed change over time. These markers could potentially be used to monitor disease progression in AD...
  11. doi request reprint New research criteria for the diagnosis of Alzheimer's disease applied in a memory clinic population
    F H Bouwman
    Alzheimer Center and Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands
    Dement Geriatr Cogn Disord 30:1-7. 2010
    ..This study applies the criteria in a memory clinic population, using clinical criteria as the reference criterion...
  12. doi request reprint CSF biomarkers in relationship to cognitive profiles in Alzheimer disease
    A E van der Vlies
    Department of Neurology and Alzheimer Center, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    Neurology 72:1056-61. 2009
    ..To investigate the relationship between CSF biomarkers and cognitive profiles in Alzheimer disease (AD)...
  13. ncbi request reprint Optimizing patient care and research: the amsterdam dementia cohort
    Wiesje M van der Flier
    Alzheimer Center, Department of Neurology, VU University Medical Center, Neuroscience Campus Amsterdam, Amsterdam, The Netherlands Department of Epidemiology and Biostatistics, VU University Medical Center, Neuroscience Campus Amsterdam, Amsterdam, The Netherlands
    J Alzheimers Dis 41:313-27. 2014
    ..By answering research questions closely related to clinical practice, the results of our research can be looped back to improve clinical work-up for our patients. ..
  14. ncbi request reprint Apolipoprotein E genotype influences presence and severity of delusions and aggressive behavior in Alzheimer disease
    Wiesje M van der Flier
    Department of Neurology and Alzheimer Center, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    Dement Geriatr Cogn Disord 23:42-6. 2007
    ..We investigated differences in the prevalence and severity of 10 neuropsychiatric and behavioral symptoms according to apolipoprotein E (APOE) genotype and dementia severity in Alzheimer disease (AD)...
  15. ncbi request reprint Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI
    M Ewers
    Department of Psychiatry, Ludwig Maximilian University, Munich, Germany
    Neurology 69:2205-12. 2007
    ..However, a standard quantitative criterion of p-tau has not been evaluated...